The nation of Zimbabwe has rejected a substantial American healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on confidential biological samples.
This move became public after a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government representative later stated that the US was demanding access to biological samples for scientific study and commercial gain while was unwilling to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for further dialogue to secure a deal suitable to all parties so the nation's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a related deal with the US after legal challenges were filed about the security of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to boost transparency and responsibility.
Based on statements, 16 African countries have to date signed similar agreements, constituting over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our country would supply the basic resources for scientific discovery with no certainty that the end products would be accessible to our population if a future health crisis emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks previously set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This system is intended to ensure that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further dialogue with our US partners on how future co-operation could be designed in a way that honours the independence and interests of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the government's concerns, but urged that talks should continue since much of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns exist, including those relating to information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
The situation emphasises the ongoing tensions between receiving much-needed international aid and safeguarding local interests in an ever more data-driven world.